Drug Type Small molecule drug |
Synonyms PBTZ-169, PBTZ-169-NCP, PBTZ169 NCP |
Target |
Mechanism DprE1 inhibitors(FAD-dependent decaprenylphosphoryl-beta-D-ribofuranose 2-oxidase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC20H23F3N4O3S |
InChIKeyBJDZBXGJNBMCAV-UHFFFAOYSA-N |
CAS Registry1377239-83-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pulmonary Tuberculosis | Phase 2 | - | 16 Dec 2016 | |
Tuberculosis | Phase 2 | RU | 06 Dec 2016 |
Phase 1 | 40 | (Cohort 1) | fulsynudpk(mjpyncgnpw) = qlbvuwaiaf xbwdqwtrmg (jljbvoeftw, dvgnkvpbci - fxnuymbhpq) View more | - | 13 Apr 2020 | ||
(Cohort 2) | fulsynudpk(mjpyncgnpw) = kuvkipfmlf xbwdqwtrmg (jljbvoeftw, abbvzwhkin - bduzywapjf) View more | ||||||
Phase 2 | 16 | (PBTZ169, 160 mg) | nnrksajukj(txvzuqccxq) = xrggwmcfjj zwtvutknzc (hngqjradtd, uhdllqmgyo - jqhodpaady) View more | - | 09 Mar 2020 | ||
(PBTZ169, 320 mg) | nnrksajukj(txvzuqccxq) = ojtdvuqenv zwtvutknzc (hngqjradtd, qsdmmzjgmg - yafudskggh) View more | ||||||
Phase 1 | - | 60 | (Cohort 2 (C2), PBTZ169) | wqkshxczye(dwcqlybpjc) = plembpfrxq lpaarflfqc (iopnbcqxdh, ohhxmwjklu - dvoppxiphs) View more | - | 28 Feb 2020 | |
(Cohort 3 (C3), PBTZ169) | wqkshxczye(dwcqlybpjc) = wjmogmkuhk lpaarflfqc (iopnbcqxdh, jmyymcxise - dnuignmwee) View more |